Tweet
All,
Currently, there is no FDA-approved medication that specifically targets evaporative dry eye.
Mimetogen Pharmaceuticals has positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles.
MIM-D3, or known/labeled as "Tavilermide". Mimetogen’s lead compound is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. Development is moving along...
Currently, there is no FDA-approved medication that specifically targets evaporative dry eye.
Mimetogen Pharmaceuticals has positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles.
MIM-D3, or known/labeled as "Tavilermide". Mimetogen’s lead compound is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. Development is moving along...